Anti-NGF antibodies and uses thereof
AssigneeInvetx, Inc.
InventorsWilliam Brondyk, Jordan Willis, Leila Sevigny
Life of this patent
Estimating the term…
Abstract
The invention provides novel anti-NGF proteins, antibodies, and NGF-binding fragments thereof which inhibit association of NGF with TrkA and/or p75 and are suitable for administration to a canine or feline subject. The invention also provides novel compositions and methods of treating pain or eliciting an analgesic effect in a canine or feline subject, comprising administering an effective amount of an anti-NGF protein, antibody or fragment thereof. The methods and compositions are used to treat or prevent NGF-related disorders.
Claims27
An antigen binding protein that specifically binds to nerve growth factor (NGF), which comprises:
- a heavy chain variable domain (VH) which comprises:
- a heavy chain complementarity determining region 1 (VH-CDR1) which comprises GLSLTSX7SMX10 (SEQ ID NO:214), wherein X7 comprises A, D, N, or S, and X10 comprises S or V;
- a heavy chain complementarity determining region 2 (VH-CDR2) which comprises X1X2SNX5GT (SEQ ID NO:215), wherein X1 comprises I or L, X2 comprises W or Y, and X5 comprises G or R;
- and
- a heavy chain complementarity determining region 3 (VH-CDR3) which comprises ASIYYYX7AX9YLHWYFDX17 (SEQ ID NO:216), wherein X7 comprises D or E, X9 comprises D or E, and X17 comprises E or F;
- and
- a light chain variable domain (VL), which comprises:
- a light chain complementarity determining region 1 (VL-CDR1) which comprises RASX4GIX7X8NLS (SEQ ID NO:217), wherein X4 comprises E or K, X7 comprises A, Q, or S, and X8 comprises K or N;
- a light chain complementarity determining region 2 (VL-CDR2) which comprises AX2X3X4LHS (SEQ ID NO:218), wherein X2 comprises Q or T, X3 comprises D or S, and X4 comprises I, N, or V;
- and
- a light chain complementarity determining region 3 (VL-CDR3) which comprises QQGX4KWPLT (SEQ ID NO:219), wherein X4 comprises F, W, or Y.
Dependencies are inferred from the claim text.